{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:38:56Z","timestamp":1792759136405,"version":"4.5.0"},"reference-count":42,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Autifony Therapeutics Ltd"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Voltage-gated Kv3.1 and KV3.2 potassium channels are mainly located on parvalbumin (PV) containing interneurons, where they play a key role in synchronising the coordinated firing of pyramidal neurons and regulating cognitive function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>We aim to explore the efficacy of acute treatment with AUT00206 (5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-me]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione), a novel and selective positive modulator of Kv3.1\/3.2 channels, to improve cognitive and social behaviour deficits in our validated animal model relevant to schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Female Lister Hooded rats were treated with phencyclidine for 7\u2009days, followed by a 7-day washout (scPCP). The efficacy of AUT00206 was tested in the novel object recognition (NOR), reversal learning (RL) and social interaction (SI) paradigms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The cognitive and social behaviour deficits induced by scPCP were significantly attenuated by AUT00206 (10 and 30\u2009mg\/kg) in the three behavioural tasks. These data demonstrate, for the first time, the efficacy of a novel Kv3.1\/3.2 channel modulator, AUT00206, in two cognitive domains (short-term recognition memory and an aspect of cognitive flexibility) and an aspect of negative symptoms in a validated animal model of schizophrenia symptomatology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Modulation of Kv3.1\/3.2 channels on PV interneurons could be an important novel approach for the treatment of schizophrenia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261473459","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:23:15Z","timestamp":1786533795000},"page":"1660-1669","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["AUT00206, a novel and selective Kv3.1\/3.2 channel modulator, restores cognitive dysfunction and negative symptoms in an animal model for schizophrenia symptomatology"],"prefix":"10.1177","volume":"40","author":[{"given":"Marianne","family":"Leger","sequence":"first","affiliation":[{"name":"Unicaen, Inserm, Comete, GIP Cyceron, Normandie Univ, Caen, France"},{"name":"Division of Pharmacy &amp; Optometry, University of Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cadinu","sequence":"additional","affiliation":[{"name":"Division of Pharmacy &amp; Optometry, University of Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Division of Pharmacy &amp; Optometry, University of Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Marasco","sequence":"additional","affiliation":[{"name":"Autifony SRL, Istituto di Ricerca Pediatrica Citta\u2019 della Speranza, Autifony Therapeutics Limited, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Alvaro","sequence":"additional","affiliation":[{"name":"Stevenage Bioscience Catalyst Incubator, Autifony Therapeutics Ltd, Stevenage, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Umbricht","sequence":"additional","affiliation":[{"name":"Stevenage Bioscience Catalyst Incubator, Autifony Therapeutics Ltd, Stevenage, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Large","sequence":"additional","affiliation":[{"name":"Stevenage Bioscience Catalyst Incubator, Autifony Therapeutics Ltd, Stevenage, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-898X","authenticated-orcid":false,"given":"Ben","family":"Grayson","sequence":"additional","affiliation":[{"name":"Division of Pharmacy &amp; Optometry, University of Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2717-9739","authenticated-orcid":false,"given":"Joanna C.","family":"Neill","sequence":"additional","affiliation":[{"name":"Division of Pharmacy &amp; Optometry, University of Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4702-4785","authenticated-orcid":false,"given":"Michael K.","family":"Harte","sequence":"additional","affiliation":[{"name":"Division of Pharmacy &amp; Optometry, University of Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Abdul-Monim Z Neill JC Reynolds GP (2007) Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. Journal of Psychopharmacology 21(2): 198\u2013205. https:\/\/doi.org\/10.1177\/0269881107067097","DOI":"10.1177\/0269881107067097"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Abdul-Monim Z Reynolds GP Neill JC (2003) The atypical antipsychotic ziprasidone but not haloperidol improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. Journal of Psychopharmacology 17(1): 57\u201365. https:\/\/doi.org\/10.1177\/0269881103017001700","DOI":"10.1177\/0269881103017001700"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Amitai N Kuczenski R Behrens MM et al. (2012) Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology 62(3): 1422-31. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.008","DOI":"10.1016\/j.neuropharm.2011.01.008"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Angelescu I Kaar SJ Marques TR et al. (2022) The effect of AUT00206 a Kv3 potassium channel modulator on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. Journal of Psychopharmacology 36(9): 1061\u20131069. https:\/\/doi.org\/10.1177\/02698811221122031","DOI":"10.1177\/02698811221122031"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Bartos M Vida I Jonas P (2007) Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nature Reviews Neuroscience 8(1): 45\u201356. https:\/\/doi.org\/10.1038\/nrn2044","DOI":"10.1038\/nrn2044"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Bromet EJ Fennig S (1999) Epidemiology and natural history of schizophrenia. Biol Psychiatry 46(7): 871\u2013881. https:\/\/doi.org\/10.1016\/S0006-3223(99)00153-5","DOI":"10.1016\/S0006-3223(99)00153-5"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Cadinu D Grayson B Podda G et al. (2018) NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments an update. Neuropharmacology 142: 41\u201362. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.11.045","DOI":"10.1016\/j.neuropharm.2017.11.045"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Caillard O Moreno H Schwaller B et al. (2000) Role of the calcium-binding protein parvalbumin in short-term synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America 97(24): 13372\u201313377. https:\/\/doi.org\/10.1073\/pnas.230362997","DOI":"10.1073\/pnas.230362997"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Dienel SJ Lewis DA (2019) Alterations in cortical interneurons and cognitive function in schizophrenia. Neurobiology of Disease 131: 104208. https:\/\/doi.org\/10.1016\/j.nbd.2018.06.020","DOI":"10.1016\/j.nbd.2018.06.020"},{"key":"e_1_3_2_11_1","doi-asserted-by":"crossref","unstructured":"Glausier JR Lewis DA (2017) GABA and schizophrenia: Where we stand and where we need to go. Schizophrenia Research 181: 2\u20133. https:\/\/doi.org\/10.1016\/j.schres.2017.01.050","DOI":"10.1016\/j.schres.2017.01.050"},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Gonzalez-Burgos G Hashimoto T Lewis DA (2010) Alterations of cortical GABA neurons and network oscillations in schizophrenia. Current Psychiatry Reports 12(4): 335\u2013344. https:\/\/doi.org\/10.1007\/s11920-010-0124-8","DOI":"10.1007\/s11920-010-0124-8"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Grayson B Idris NF Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research 184(1): 31\u201338. https:\/\/doi.org\/10.1016\/j.bbr.2007.06.012","DOI":"10.1016\/j.bbr.2007.06.012"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Grayson B Podda G Cilia J et al. (2025) The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia. Journal of Psychopharmacology 40(3). https:\/\/doi.org\/10.1177\/02698811251381246","DOI":"10.1177\/02698811251381246"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-195809000-00007"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Hegeman DJ Hong ES Hern\u00e1ndez VM et al. (2016) The external globus pallidus: Progress and perspectives. European Journal of Neuroscience 43(10): 1239\u20131265. https:\/\/doi.org\/10.1111\/ejn.13196","DOI":"10.1111\/ejn.13196"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Homayoun H Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. The Journal of Neuroscience 27(43): 11496\u201311500. https:\/\/doi.org\/10.1523\/JNEUROSCI.2213-07.2007","DOI":"10.1523\/JNEUROSCI.2213-07.2007"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Idris N Neill J Grayson B et al. (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: Involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology 208(1): 23\u201336. https:\/\/doi.org\/10.1007\/s00213-009-1702-5","DOI":"10.1007\/s00213-009-1702-5"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Kaar SJ Angelescu I Nour MM et al. (2022) The effects of AUT00206 a novel Kv3.1\/3.2 potassium channel modulator on task-based reward system activation: A test of mechanism in schizophrenia. Psychopharmacology 239(10): 3313\u20133323. https:\/\/doi.org\/10.1007\/s00213-022-06216-3","DOI":"10.1007\/s00213-022-06216-3"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Kaar SJ Nottage JF Angelescu I et al. (2024) Gamma oscillations and potassium channel modulation in schizophrenia: Targeting GABAergic dysfunction. Clinical EEG and Neuroscience 55(2): 203\u2013213. https:\/\/doi.org\/10.1177\/15500594221148643","DOI":"10.1177\/15500594221148643"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Kaczmarek LK Zhang Y (2017) Kv3 Channels: Enablers of rapid firing neurotransmitter release and neuronal endurance. Physiological Reviews 97(4): 1431\u20131468. https:\/\/doi.org\/10.1152\/physrev.00002.2017","DOI":"10.1152\/physrev.00002.2017"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Landreth K Simanaviciute U Fletcher J et al. (2020) Dissociating the effects of distraction and proactive interference on object memory through tests of novelty preference. Brain Neurosci Adv 5. https:\/\/doi.org\/10.1177\/23982128211003199","DOI":"10.1177\/23982128211003199"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Lewis DA (2014) Inhibitory neurons in human cortical circuits: Substrate for cognitive dysfunction in schizophrenia. Current Opinion in Neurobiology 26: 22\u201326. https:\/\/doi.org\/10.1016\/j.conb.2013.11.003","DOI":"10.1016\/j.conb.2013.11.003"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Luby ED Cohen BD Rosenbaum G et al. (1959) Study of a new schizophrenomimetic drug; sernyl. Archives of Neurology and Psychiatry 81(3): 363\u2013369. https:\/\/doi.org\/10.1001\/archneurpsyc.1959.02340150095011","DOI":"10.1001\/archneurpsyc.1959.02340150095011"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"Mann EO Paulsen O (2007) Role of GABAergic inhibition in hippocampal network oscillations. Trends in Neurosciences 30(7): 343\u2013349. https:\/\/doi.org\/10.1016\/j.tins.2007.05.003","DOI":"10.1016\/j.tins.2007.05.003"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"McLean SL Neill JC Idris NF et al. (2010) Effects of asenapine olanzapine and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behavioural Brain Research 214(2): 240\u2013247. https:\/\/doi.org\/10.1016\/j.bbr.2010.05.043","DOI":"10.1016\/j.bbr.2010.05.043"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"Nakazawa K Zsiros V Jiang Z et al. (2012) GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology 62(3): 1574\u20131583. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.022","DOI":"10.1016\/j.neuropharm.2011.01.022"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Neill JC Barnes S Cook S et al. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism. Pharmacology & Therapeutics 128(3): 419\u2013432. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.07.004","DOI":"10.1016\/j.pharmthera.2010.07.004"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Neill JC Grayson B Kiss B et al. (2016) Effects of cariprazine a novel antipsychotic on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. European Neuropsychopharmacology 26(1): 3\u201314. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.11.016","DOI":"10.1016\/j.euroneuro.2015.11.016"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Neill JC Harte MK Haddad PM et al. (2014) Acute and chronic effects of NMDA receptor antagonists in rodents relevance to negative symptoms of schizophrenia: A translational link to humans. European Neuropsychopharmacology 24(5): 822\u2013835. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.09.011","DOI":"10.1016\/j.euroneuro.2013.09.011"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Pratt JA Winchester C Egerton A et al. (2008) Modelling prefrontal cortex deficits in schizophrenia: Implications for treatment. British Journal of Pharmacology 153(Suppl 1): S465\u2013S470. https:\/\/doi.org\/10.1038\/bjp.2008.24","DOI":"10.1038\/bjp.2008.24"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Reynolds GP Neill JC (2016) Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. Journal of Psychopharmacology 30(11): 1141\u20131144. https:\/\/doi.org\/10.1177\/0269881116667668","DOI":"10.1177\/0269881116667668"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"Ruden JB Dugan LL Konradi C (2021) Parvalbumin interneuron vulnerability and brain disorders. Neuropsychopharmacology 46(2): 279\u2013287. https:\/\/doi.org\/10.1038\/s41386-020-0778-9","DOI":"10.1038\/s41386-020-0778-9"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Rudy B Chow A Lau D et al. (1999) Contributions of Kv3 channels to neuronal excitability. Annals of the New York Academy of Sciences 868: 304\u2013343. https:\/\/doi.org\/10.1111\/j.1749-6632.1999.tb11295.x","DOI":"10.1111\/j.1749-6632.1999.tb11295.x"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Rudy B McBain CJ (2001) Kv3 channels: Voltage-gated K+ channels designed for high-frequency repetitive firing. Trends in Neurosciences 24(9): 517\u2013526. https:\/\/doi.org\/10.1016\/S0166-2236(00)01892-0","DOI":"10.1016\/S0166-2236(00)01892-0"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Snigdha S Neill JC (2008a) Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats\u2014A preliminary investigation. Behavioural Brain Research 187(2): 489\u2013494. https:\/\/doi.org\/10.1016\/j.bbr.2007.10.012","DOI":"10.1016\/j.bbr.2007.10.012"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Snigdha S Neill JC (2008b) Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behavioural Brain Research 191(1): 26\u201331. https:\/\/doi.org\/10.1016\/j.bbr.2008.03.018","DOI":"10.1016\/j.bbr.2008.03.018"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Stubbendorff C Hale E Day HLL et al. (2023) Pharmacological modulation of Kv3 voltage-gated potassium channels regulates fear discrimination and expression in a response-dependent manner. Progress in Neuro-Psychopharmacology and Biological Psychiatry 127: 110829. https:\/\/doi.org\/10.1016\/j.pnpbp.2023.110829","DOI":"10.1016\/j.pnpbp.2023.110829"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"St\u0119pnicki P Kondej M Kaczor AA (2018) Current concepts and treatments of schizophrenia. Molecules 23(8): 2087. https:\/\/doi.org\/10.3390\/molecules23082087","DOI":"10.3390\/molecules23082087"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Tandon R Nasrallah HA Keshavan MS (2009) Schizophrenia \u201cjust the facts\u201d 4. Clinical features and conceptualization. Schizophrenia Research 110(1\u20133): 1\u201323. https:\/\/doi.org\/10.1016\/j.schres.2009.03.005","DOI":"10.1016\/j.schres.2009.03.005"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2774"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Vreugdenhil M Jefferys JG Celio MR et al. (2003) Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. Journal of Neurophysiology 89(3): 1414\u20131422. https:\/\/doi.org\/10.1152\/jn.00576.2002","DOI":"10.1152\/jn.00576.2002"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Yanagi M Joho RH Southcott SA et al. (2014) Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs. Molecular Psychiatry 19(5): 573\u2013579. https:\/\/doi.org\/10.1038\/mp.2013.49","DOI":"10.1038\/mp.2013.49"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261473459","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:51:28Z","timestamp":1792756288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261473459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/02698811261473459"],"URL":"https:\/\/doi.org\/10.1177\/02698811261473459","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}